|Day Low/High||57.80 / 61.17|
|52 Wk Low/High||65.55 / 94.22|
Express Scripts is losing its largest customer.
Levi & Korsinsky, LLP announces it has commenced an investigation of Express Scripts Holding Company ("Express Scripts") (NASDAQ:ESRX) concerning possible violations of federal securities laws.
Better-than-expected earnings from industry leaders including Caterpillar and McDonald's push the Dow to log triple-digit gains for the second day in a row, its best two-day stretch of the year.
Khang & Khang LLP (the "Firm") announces that it is investigating claims against Express Scripts Holding Company ("Express Scripts" or the "Company") (Nasdaq: ESRX) concerning possible violations of federal securities...
U.S. stock futures are set for solid gains and European stocks soar after the first round of France's elections put centrist Emmanuel Macron in the lead for the presidency.
But also remember that this week earnings will run wild, with nearly 200 members of the S&P 500 reporting.
Here are five things you must know for Monday, April 24.
Full-steam ahead for earnings season in the coming week as a range of industry leaders across a swath of sectors release their recent quarterly performances.
Its earnings are more than double what they were five years ago, but the stock price is the same.
Attorney Advertising. On March 17, 2017, the nationally recognized class-action law firm of Keller Rohrback L.
New daily health solution connects two industry leading platforms for improving health outcomes and reducing the cost of care.
Chuck Grassley is hammering the privately held drug company on its $4,500 EpiPen competitor.
I believe this president goes full Trumpian tonight, in a style that he has made all his own.
The pharmaceutical distributor is finally turning around.
It used the earning's call to pass much of the blame for high drug prices onto pharmaceutical companies.
The country's largest pharmacy benefits manager is enjoying tailwinds after reporting a big jump in year-over-year profits.
The pharmacy benefit manager shifted blame for drug pricing back to pharma companies.
Kaleo's EpiPen compeitor the Auvi-Q was released today.
The Auvi-Q was released Feb. 14, but it's unclear whether patients will break up with their current option, EpiPen, for something new.
BLL, OPK, ESRX, SKYW and DLA all were recently downgraded by TheStreet's Quant Ratings.
Jim Cramer likes European banks, plus Banco Santander, and New York Community Bancorp, too.
Jim Cramer takes a closer look at the risks: Don't measure 'Trump per share,' measure actual earnings per share.